Alnylam Pharmaceuticals Inc (ALNY)

Currency in USD
159.73
-5.31(-3.22%)
Closed·
160.20+0.47(+0.29%)
·
ALNY is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
158.68167.55
52 wk Range
149.18479.79
Key Statistics
Prev. Close
165.04
Open
166.98
Day's Range
158.68-167.55
52 wk Range
149.18-479.79
Volume
2.12M
Average Volume (3m)
2.05M
1-Year Change
-65.3168%
Book Value / Share
26.93
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALNY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
299.96
Upside
+87.79%
Members' Sentiments
Bearish
Bullish
ProTips
9 analysts have revised their earnings downwards for the upcoming period
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

Analyst Ratings

21 Buy
9 Hold
0 Sell
Ratings:
30 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 299.96
(+87.79% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BMO Capital
Buy292.00+82.81%290.00MaintainNov 05, 2026
Bernstein SocGen Group
Hold199.00+24.59%376.00MaintainNov 02, 2026
Canaccord
Buy323.00+102.22%429.00MaintainNov 02, 2026
Truist Securities
Hold225.00+40.86%-DowngradeNov 02, 2026
Barclays
Buy380.00+137.90%450.00MaintainNov 02, 2026

Alnylam Pharmaceuticals Inc SWOT Analysis


ATTR-CM Breakthrough
Amvuttra's approval with a broad label for ATTR-CM treatment positions Alnylam as a strong competitor in the expanding $6 billion market
Financial Trajectory
Analysts project Alnylam's revenue to grow from $2.2B in 2024 to $4B in 2026, with profitability expected this year despite high R&D costs
Competitive Edge
Explore how Alnylam's RNAi platform and pipeline diversity set it apart in the evolving ATTR-CM landscape, balancing opportunities and threats
Analyst Optimism
Price targets range from $250 to $500, with an average of $356, reflecting confidence in Alnylam's growth potential and market positioning
Read full SWOT analysis

Alnylam Pharmaceuticals Inc Earnings Call Summary for Q3/2026

  • Alnylam Q3 EPS of $16.26 beat est. $1.74 on $1.9B tax benefit; revenue rose 52% to $1.46B, topping $1.43B forecast; shares fell 17% to $192.38.
  • TTR franchise revenue up 59% to $1.15B, but full-year TTR sales now expected at low end of $4.2B-$4.5B range amid slower patient conversion.
  • AMVUTTRA growth hampered by Medicare Advantage restrictions, proposed 340B rule changes, and slower physician-to-patient conversion despite expanded sales force.
  • Company delays 2027 guidance to mid-Feb from usual January JPM conference, citing need for visibility on ordering patterns and site-of-care shifts.
  • Pipeline advances include TRITON-CM expansion to 2,250 patients, Phase III Huntington's study planned 2027; maintains 25%+ revenue CAGR target through 2030.
Last Updated: 2026-10-29, 09:48 a/m
Read Full Transcript

Earnings

Latest Release
Oct 29, 2026
EPS / Forecast
16.26 / 1.74
Revenue / Forecast
1.46B / 1.43B
EPS Revisions
Last 90 days

ALNY Income Statement

Compare ALNY to Peers and Sector

Metrics to compare
ALNY
Peers
Sector
Relationship
P/E Ratio
8.1x14.3x−0.2x
PEG Ratio
0.000.930.00
Price/Book
5.9x1.7x2.6x
Price / LTM Sales
4.3x2.3x2.7x
Upside (Analyst Target)
87.8%6.2%66.0%
Fair Value Upside
Unlock27.6%10.8%Unlock

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer’s disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington’s disease; ALN-5288 for Alzheimer’s disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson’s disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Employees
2500

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
95.06M70.97%15.69B
Other Institutional Investors
42.96M29.03%7.09B
Public Companies & Retail Investors
0.000.00%0.00
Total
138.02M100.00%22.78B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Capital Research and Management Company18.57%24,875,4444,105,443
FMR LLC9.00%12,054,7811,989,521

People Also Watch

237.33
PGR
+0.66%
51.24
EQT
-2.97%
174.87
HSY
+1.19%
252.67
NUE
+0.37%
49.88
CRWV
-6.12%

FAQ

What Is the Alnylam (ALNY) Stock Price Today?

The Alnylam stock price today is 159.73 USD.

What Stock Exchange Does Alnylam Trade On?

Alnylam is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Alnylam?

The stock symbol for Alnylam is "ALNY."

What Is the Alnylam Market Cap?

As of today, Alnylam market cap is 21.39B USD.

What Is Alnylam's Earnings Per Share (TTM)?

The Alnylam EPS (TTM) is 19.90.

When Is the Next Alnylam Earnings Date?

Alnylam will release its next earnings report on Feb 18, 2027.

From a Technical Analysis Perspective, Is ALNY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Alnylam Stock Split?

Alnylam has split 0 times.

How Many Employees Does Alnylam Have?

Alnylam has 2500 employees.

What is the current trading status of Alnylam (ALNY)?

As of Nov 17, 2026, Alnylam (ALNY) is trading at a price of 159.73 USD, with a previous close of 165.04 USD. The stock has fluctuated within a day range of 158.68 USD to 167.55 USD, while its 52-week range spans from 149.18 USD to 479.79 USD.

What Is Alnylam (ALNY) Price Target According to Analysts?

The average 12-month price target for Alnylam is 299.96 USD, with a high estimate of 455 USD and a low estimate of 180 USD. 21 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +87.79% Upside potential.

What Is the ALNY Premarket Price?

ALNY's last pre-market stock price is 167.45 USD. The pre-market share volume is 2,830.00, and the stock has decreased by 2.41, or 1.46%.

What Is the ALNY After Hours Price?

ALNY's last after hours stock price is 160.20 USD, the stock has decreased by 0.47, or 0.29%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.